Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

Related Keywords

Texas ,United States ,Mark Berger ,Exchange Commission ,Genprex Inc ,Astrazeneca ,Linkedin ,Facebook ,Drug Administration ,Safety Review Committee ,Increased Dose ,Final Cohort ,Trial Indicates Favorable Safety Profile ,Novel Gene Therapy ,Solid Tumor ,Fast Track Designation ,Chief Medical Officer ,Nanoparticle Delivery System ,Private Securities Litigation Reform Act ,Annual Report ,Genprex ,Nc ,